HTL26119

HTL26119 is a drug which acts as a potent and selective negative allosteric modulator behaving as a functional antagonist of the glucagon-like peptide-1 receptor (GLP-1).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

HTL26119 is a drug which acts as a potent and selective negative allosteric modulator behaving as a functional antagonist of the glucagon-like peptide-1 receptor (GLP-1). While GLP-1 receptor agonists are widely used for the treatment of obesity and diabetes, there are few antagonists known for this receptor.

However, these also have potential medical uses for indications where weight gain is desirable, such as treatment of sarcopenia in the elderly and cachexia in patients affected by conditions such as cancer and AIDS. While HTL26119 itself is unlikely to be developed for medical use, as one of the first selective antagonists for GLP-1 it has been widely used as a pharmacological tool compound for the study of the GLP-1 receptor and its signaling pathway.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365085169 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.